ArticleCancer immunology, immunotherapy : CII2020
A gene expression-based immune signature for lung adenocarcinoma prognosis.
Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity.International journal of molecular sciences · 2025Review
- A review on trends in development and translation of omics signatures in cancer.Computational and structural biotechnology journal · 2024Review
- Molecular mechanisms and clinicopathological characteristics of inhibin βA in thyroid cancer metastasis.International journal of molecular medicine · 2024Article
- Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients.Scientific reports · 2023Article
- Identification of New Prognostic Genes and Construction of a Prognostic Model for Lung Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2023Article
- Development and validation of an immune-related gene signature for prognosis in Lung adenocarcinoma.IET systems biology · 2023Article
- Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung.Cancer prevention research (Philadelphia, Pa.) · 2022Observational
- Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.EBioMedicine · 2022Review
- An advanced non-small cell lung cancer patient withAnnals of translational medicine · 2022Article
- Prognostic Value of Genomic Instability of mFrontiers in cell and developmental biology · 2022Article
- Analysis of the tumor immune environment identifies an immune gene set-based prognostic signature in non-small cell lung cancer.Annals of translational medicine · 2022Article
- Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma.Theranostics · 2021Article
- Elastic Net Models Based on DNA Copy Number Variations Predicts Clinical Features, Expression Signatures, and Mutations in Lung Adenocarcinoma.Frontiers in genetics · 2021Article
- A Novel Early-Stage Lung Adenocarcinoma Prognostic Model Based on Feature Selection With Orthogonal Regression.Frontiers in cell and developmental biology · 2020Article
- Potential Genes Associated with the Survival of Lung Adenocarcinoma Were Identified by Methylation.Computational and mathematical methods in medicine · 2020Article
- Tumor Profiling at the Service of Cancer Therapy.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) has become the most frequent histologic type of lung cancer in the past several decades. Recent successes with immune checkpoint blockade therapy have demonstrated that the manipulation of the immune system is a very potent treatment for LUAD. This study aims to explore the role of immune-related genes in the development of LUAD and establish a signature that can predict overall survival for LUAD patients.
methodsTo identify the differential expression genes (DEGs) between normal and tumor tissues, we developed an analysis strategy to combine an independent-sample design and a paired-sample design using RNA-seq transcriptomic profiling data of The Cancer Genome Atlas LUAD samples. Further, we selected prognostic markers from DEGs and evaluated their prognostic value in a prediction model.
resultsWe identified and validated PD1, PDL1 and CTLA4 genes as prognostic markers, which are well-known immune checkpoints, and revealed two new potential prognostic immune checkpoints for LUAD, HHLA2 (logFC = 2.55, FDR = 1.89 × 10
conclusionsThe identified DEG features may serve as potential biomarkers for prognosis prediction of LUAD patients and immunotherapy. Based on that assumption, we identified a gene expression-based immune signature for lung adenocarcinoma prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.